Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.

Lorenzen, S; Duyster, J; Lersch, C; von Delius, S; Hennig, M; Bredenkamp, R; Peschel, C; Lordick, F

Lorenzen, S; Duyster, J; Lersch, C; von Delius, S; Hennig, M; Bredenkamp, R; Peschel, C; Lordick, F.

Affiliation

Lorenzen S; 3rd Department of Internal Medicine (Haematology/Medical Oncology), Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, Munich D-81675, Germany.

Br J Cancer ; 92(12): 2129-33, 2005 Jun 20.

Article in En | MEDLINE | ID: mdl-15942631

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Squamous Cell/drug therapy; Esophageal Neoplasms/drug therapy; Adenocarcinoma/secondary; Aged; Capecitabine; Carcinoma, Squamous Cell/secondary; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms/pathology; Feasibility Studies; Female; Fluorouracil/analogs & derivatives; Humans; Male; Middle Aged; Survival Analysis; Taxoids/administration & dosage; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2005 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google